Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food-effect Study of SH-1028 in Healthy Subjects
NCT03973632Phase 1Unknown
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of rilertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Area under the plasma concentration-time curve from zero to infinity at 72 hours, Area under the plasma concentration-time curve from zero to last measurable concentration at 72 hours and 1 more. Status: unknown.
02
Drugs
rilertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03973632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03973632.